Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

37 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A phase I safety, pharmacological and biological study of the farnesyl protein transferase inhibitor, tipifarnib and capecitabine in advanced solid tumors.
Gore L, Holden SN, Cohen RB, Morrow M, Pierson AS, O'Bryant CL, Persky M, Gustafson D, Mikule C, Zhang S, Palmer PA, Eckhardt SG. Gore L, et al. Among authors: holden sn. Ann Oncol. 2006 Nov;17(11):1709-17. doi: 10.1093/annonc/mdl282. Epub 2006 Sep 15. Ann Oncol. 2006. PMID: 16980604 Free article. Clinical Trial.
Assessment of the biological and pharmacological effects of the alpha nu beta3 and alpha nu beta5 integrin receptor antagonist, cilengitide (EMD 121974), in patients with advanced solid tumors.
Hariharan S, Gustafson D, Holden S, McConkey D, Davis D, Morrow M, Basche M, Gore L, Zang C, O'Bryant CL, Baron A, Gallemann D, Colevas D, Eckhardt SG. Hariharan S, et al. Ann Oncol. 2007 Aug;18(8):1400-7. doi: 10.1093/annonc/mdm140. Ann Oncol. 2007. PMID: 17693653 Free article. Clinical Trial.
A phase I biological and pharmacologic study of the heparanase inhibitor PI-88 in patients with advanced solid tumors.
Basche M, Gustafson DL, Holden SN, O'Bryant CL, Gore L, Witta S, Schultz MK, Morrow M, Levin A, Creese BR, Kangas M, Roberts K, Nguyen T, Davis K, Addison RS, Moore JC, Eckhardt SG. Basche M, et al. Among authors: holden sn. Clin Cancer Res. 2006 Sep 15;12(18):5471-80. doi: 10.1158/1078-0432.CCR-05-2423. Clin Cancer Res. 2006. PMID: 17000682 Clinical Trial.
A phase I and pharmacokinetic study of BAY59: a novel taxane.
Ramnath N, Hamm J, Schwartz G, Holden S, Eckhardt SG, Vredenburg MR, Bernacki RJ, Lathia C, Kanter P, Creaven PJ. Ramnath N, et al. Oncology. 2004;67(2):123-9. doi: 10.1159/000080998. Oncology. 2004. PMID: 15539916 Clinical Trial.
A phase I and pharmacokinetic study of exisulind and docetaxel in patients with advanced solid tumors.
Witta SE, Gustafson DL, Pierson AS, Menter A, Holden SN, Basche M, Persky M, O'Bryant CL, Zeng C, Baron A, Long ME, Gibbs A, Kelly K, Bunn PA Jr, Chan DC, Pallansch P, Eckhardt SG. Witta SE, et al. Among authors: holden sn. Clin Cancer Res. 2004 Nov 1;10(21):7229-37. doi: 10.1158/1078-0432.CCR-03-0181. Clin Cancer Res. 2004. PMID: 15534096 Clinical Trial.
A phase I pharmacological and biological study of PI-88 and docetaxel in patients with advanced malignancies.
Chow LQ, Gustafson DL, O'Bryant CL, Gore L, Basche M, Holden SN, Morrow MC, Grolnic S, Creese BR, Roberts KL, Davis K, Addison R, Eckhardt SG. Chow LQ, et al. Among authors: holden sn. Cancer Chemother Pharmacol. 2008 Dec;63(1):65-74. doi: 10.1007/s00280-008-0712-z. Epub 2008 Mar 5. Cancer Chemother Pharmacol. 2008. PMID: 18320191 Free PMC article. Clinical Trial.
Safety and pharmacokinetic study of RPI.4610 (ANGIOZYME), an anti-VEGFR-1 ribozyme, in combination with carboplatin and paclitaxel in patients with advanced solid tumors.
Kobayashi H, Eckhardt SG, Lockridge JA, Rothenberg ML, Sandler AB, O'Bryant CL, Cooper W, Holden SN, Aitchison RD, Usman N, Wolin M, Basche ML. Kobayashi H, et al. Among authors: holden sn. Cancer Chemother Pharmacol. 2005 Oct;56(4):329-36. doi: 10.1007/s00280-004-0968-x. Epub 2005 May 20. Cancer Chemother Pharmacol. 2005. PMID: 15906031 Clinical Trial.
Angiogenesis inhibitors in clinical development for lung cancer.
Herbst RS, Hidalgo M, Pierson AS, Holden SN, Bergen M, Eckhardt SG. Herbst RS, et al. Among authors: holden sn. Semin Oncol. 2002 Feb;29(1 Suppl 4):66-77. doi: 10.1053/sonc.2002.31527. Semin Oncol. 2002. PMID: 11894016 Review.
37 results